Introduction {#sec1}
============

Fluorescence has a broad application as a modality for in vitro and in vivo imaging.^[@ref1],[@ref2]^ In the clinical field, an increasing interest in fluorescence imaging has been triggered by the introduction of fluorescence camera systems that can be applied during surgery.^[@ref3]−[@ref5]^ In this context, real-time fluorescence imaging is utilized to visualize a distinct (e.g., diseased) tissue type within the surgical field. The value of fluorescence for surgical guidance is limited by signal attenuation, and therefore the technique only provides accurate guidance in superficial applications (\<1 cm) and does not allow for preoperative imaging.^[@ref6],[@ref7]^ On the other hand, γ rays produced by isotopes such as ^99m^Tc and ^111^In are not held back by this characteristic and can penetrate human tissue without limitations, which makes them suited for noninvasive (preoperative) imaging.^[@ref8]^

To combine these features, tracers that contain both a fluorescent and radioactive imaging label can be designed. In these so-called "dual-labeled", "bimodal", or rather "hybrid" tracers, the fluorescent and radioactive signatures complement each other, creating a "best-of-both-worlds" scenario in clinical image-guided surgery applications.^[@ref8]−[@ref10]^ Today, hybrid tracers containing cyanine dyes ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}A, left) are constructed by conjugating branched linkers (in white) bearing both the radioactive label (in red; mostly a chelate) and the fluorescent dye (in blue) to the targeting vector (in green), i.e., containing end-conjugated dyes as introduced by Josephson et al.^[@ref11],[@ref12]^ In practice, however, such end-conjugated cyanine-dye-based hybrid tracers make use of redundant spacers and suffer from a low synthetic yield due to the larger number of synthetic steps with concomitantly low yields.

![(A) Schematic Overview of the Original Multifunctional Single-Attachment-Point RGD-based Hybrid Tracer Design (End-Labeling; Left, with the Dye in Blue, Chelate in Red, Targeting Moiety in Green and Linker in White) and New Heterobifunctional RGD-based Hybrid Tracer Wherein the Dye Is Used as Linker (Right, with the Dye in Blue, DTPA in Red, and Targeting Moiety in Green). (B) Chemical Structures of the Reference Compound **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (End-Labeling) and (C) **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (Modular, Heterobifunctional Design Employing a Cy5 Dye as Spacer between Chelate and Targeting Moiety Using Click Chemistry)](ao-2019-01484q_0004){#sch1}

As an alternative to end-labeling strategies, we hypothesized that it may be possible to improve the ease of synthesis by using click chemistry, which has been on the rise ever since the investigation of the 1,3-dipolar cycloaddition by Huisgen in the 1960s. After about four decades, Sharpless and Meldal independently discovered the copper-catalyzed click reaction in which 1,4-disubstituted 1,2,3-triazoles were formed from azides and terminal alkynes. The toxicity of copper prompted Sletten and Bertozzi to explore copper-free click chemistry using strain-promoted azide--alkyn cyclocaddition (SPAAC). SPAAC has been of great interest in the field of molecular imaging where radio- and fluorescence-labeling strategies have been independently studied.^[@ref2],[@ref13]^ The required ligands (e.g., dibenzocyclooctyne (DBCO) or bicyclo\[6.1.0\]nonyne (BCN) groups) are commercially available, and this reaction is one of the most-studied in the field of bioorthogonal chemistry. Despite the fact that click chemistry for in vivo fluorescence imaging has already been applied,^[@ref14],[@ref15]^ the synthesis of click-chemistry-based hybrid tracers is, to date, only described using antibodies and not peptides.^[@ref16]^ A design wherein the fluorophore also fulfills the role as linker ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, right) has, to the best of our knowledge, only been researched using 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes.^[@ref16]^ Use of a small-molecule, copper-free click-based design incorporating cyanine dyes as a linker has not yet been described.

The aim of this study was therefore to evaluate the use of a click-chemistry-based labeling strategy for peptides to improve the ease of synthesis and synthetic yield of peptide-based hybrid tracers while creating a conjugated tracer with a more compact structure ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). To study the influence of chemically introduced alterations in the context of earlier end-conjugated tracer developments (resulting in reference tracer **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**;^[@ref17]^[Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}B), the well-known α~v~β~3~-integrin-targeting RGD peptide (c\[RGDyK\]) was chosen as the targeting moiety.^[@ref17]−[@ref19]^ In the novel tracer design, the heterobifunctional dye functions as a linker that enables the coupling of both a chelator, e.g., diethylenetriaminepentaacetic acid (DTPA), and the targeting vector (**resulting in DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**; [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}C). DBCO and BCN were chosen as click handles due to their availability and reaction kinetics (*k* = 310 and 140 × 10^--3^ M^--1^ s^--1^, respectively). As a constant factor in both the end-labeled and click-chemistry-based strategies, the heterobifunctional Cy5 dye was incorporated in the tracer design based on the outcome of previous studies; a tracer's biodistribution can be optimized by shielding the dye from the environment.^[@ref20]^ Previous studies wherein the fluorescent component of a hybrid tracer was optimized to provide beneficial properties for in vivo use resulted in the selection of **N**~**3**~**(SO**~**3**~**)-Cy5-COOH**.^[@ref17],[@ref21],[@ref22]^ As such, the use of this dye was---together with the DTPA molecule and RGD targeting vector---implemented as a constant factor in both the end-labeled (reference) and click-chemistry-based synthesis strategies. The chemical and photophysical properties, along with in vivo biodistribution, of the RGD-based hybrid tracers were analyzed using photophysical analysis and biological evaluation in vitro and in vivo as outlined by the European Association of Nuclear Medicine.^[@ref41]^

Results and Discussion {#sec2}
======================

Chemistry {#sec2.1}
---------

As a general synthon for all compounds in this study, the **Phth(SO**~**3**~**)-Cy5-COOH** dye was prepared. Following its coupling to c\[RGDyK\] using standard NHS chemistry, this heterobifunctional Cy5 dye functioned as a linker unit for further synthetic modifications. By using an adapted version of the Gabriel synthesis, the amine could easily be liberated. Subsequent diazotransfer^[@ref23]^ with 1*H*-imidazolesulfonyl azide·HCl could be performed, which resulted in **N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**. This modification supported SPAAC with either DBCO--DTPA or BCN--DTPA, resulting in **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

Photophysical and Chemical Properties {#sec2.2}
-------------------------------------

To assess the influence that the chemical alterations exerted on the dyes' and hybrid tracers' photophysical properties, the molar extinction coefficient (ε) and quantum yield (Φ~F~) were assessed to evaluate the brightness (ε· Φ~F~).^[@ref7]^

Solvent polarity plays a large role in ε; the ε value of **N**~**3**~**(SO**~**3**~**)-Cy5-COOH** in dimethyl sulfoxide (DMSO) was reduced by 40% when changing to H~2~O (218 × 10^3^ M^--1^ cm^--1^ in DMSO vs 131 × 10^3^ M^--1^ cm^--1^ in H~2~O), and a 13% reduction was seen when phosphate-buffered saline (PBS) was used (189 × 10^3^ M^--1^ cm^--1^), which is in line with previous results.^[@ref22]^ The relative Φ~F~ of **N**~**3**~**(SO**~**3**~**)-Cy5-COOH** was similar to **methyl-Cy5-COOH**([@ref22]) (precursor to **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**; Φ~F~ = 13% for both dyes in PBS).

The brightness of the precursor for the triazole-based hybrid tracers (**N**~**3**~**(SO**~**3**~**)-Cy5-COOH**) was in the same range as the precursor for the end-labeled design (**methyl-Cy5-COOH**; 29 × 10^3^ vs 28 × 10^3^ M^--1^ cm^--1^, respectively). When the click reaction incorporating DBCO was used to form **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, virtually no change in brightness was observed compared to **N**~**3**~**(SO**~**3**~**)-Cy5-COOH** (23 × 10^3^ vs 25 × 10^3^ M^--1^ cm^--1^, respectively). The brightness was, however, enhanced to 40 × 10^3^ M^--1^ cm^--1^ for **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**. The reference tracer **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** had an even higher brightness (50 × 10^3^ M^--1^ cm^--1^). *Cis*--*trans* isomerization around the polymethine bridge plays a large role in the differences in brightness,^[@ref24]\ ,[@ref25]^ but since the BCN moiety is considerably less bulky than its DBCO counterpart, it seems that intra- or intermolecular interactions other than steric hindrance caused this effect.

By using the shake-flask method with radiolabeled hybrid tracer, the partition coefficients in octanol/H~2~O (log *P*~(o/w)~) were determined for all three hybrid tracers as log *P*~(o/w)~ = −2.55 ± 0.10, −1.45 ± 0.03, and −2.67 ± 0.12 for **\[**^**99mTc**^**\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, **\[**^**99mTc**^**\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, and **\[**^**99mTc**^**\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, respectively ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). These data indicated, surprisingly, that **\[**^**99mTc**^**\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** was the most lipophilic compound of the three, while **\[**^**99mTc**^**\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and the reference tracer **\[**^**99mTc**^**\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** had similar lipophilicities.

###### Photophysical and Chemical Properties of Fluorophore**s (H~2~N(SO~3~)-Cy5-COOH, N~3~(SO~3~)-Cy5-COOH)** and Hybrid Tracers (**DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**)[a](#t1fn1){ref-type="table-fn"}

                                                                                          λ~ex~/λ~em~ (Stokes shift; nm)   Molar absorbance coefficient (ε; · 10^5^ M^--1^ cm^--1^)                                                                                                                                                                 
  --------------------------------------------------------------------------------------- -------------------------------- ---------------------------------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- -------------- ------------------------------------- ----------------------------------
  **N**~**3**~**(SO**~**3**~**)-Cy5-COOH**[b](#t1fn2){ref-type="table-fn"}                656/676 (20)                     644/662 (18)                                               2.18                               1.31                               1.89                               13             2.5                                   [d](#t1fn4){ref-type="table-fn"}
  **methyl-(SO**~**3**~**)Cy5-COOH**,^[@ref22]^ [b](#t1fn2){ref-type="table-fn"}          653/672 (19)                     642/658 (16)                                               2.38                               1.76                               2.12                               13             2.8                                   [d](#t1fn4){ref-type="table-fn"}
  **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**[c](#t1fn3){ref-type="table-fn"}   654/675 (21)                     644/663 (19)^[@ref21]^                                     [d](#t1fn4){ref-type="table-fn"}   [d](#t1fn4){ref-type="table-fn"}   [d](#t1fn4){ref-type="table-fn"}   19^[@ref21]^   5.0[e](#t1fn5){ref-type="table-fn"}   --2.67 ± 0.12
  **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**                                655/674 (19)                     646/665 (19)                                               [d](#t1fn4){ref-type="table-fn"}   [d](#t1fn4){ref-type="table-fn"}   [d](#t1fn4){ref-type="table-fn"}   12             2.3[e](#t1fn5){ref-type="table-fn"}   --2.55 ± 0.10
  **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**                                 645/665 (20)                     655/674 (19)                                               [d](#t1fn4){ref-type="table-fn"}   [d](#t1fn4){ref-type="table-fn"}   [d](#t1fn4){ref-type="table-fn"}   21             4.0[e](#t1fn5){ref-type="table-fn"}   --1.45 ± 0.03

Note that for the determination of log  *P*(~o/w~), the following radiolabeled tracers were used: **\[**^**99m**^**Tc\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, **\[**^**99m**^**Tc\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, **\[**^**99m**^**Tc\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**.

Precursor to hybrid tracer.

Reference tracer.

Not determined.

Estimated by using the ε of the free fluorophore.

Serum Interaction and Chemical Stability {#sec2.3}
----------------------------------------

Depending on their functionalization, cyanine dyes can form strong noncovalent bonds with serum proteins, e.g., albumin. In addition, the dyes can also be metabolically degraded,^[@ref17],[@ref21],[@ref22],[@ref26],[@ref27]^ yielding circulation of tracer fragments in an in vivo setting. Such degradation underlines the pressing need for serum interaction assays during preclinical research. A serum binding assay for the two triazole-containing RGD-targeting hybrid tracers revealed no significant differences between the two click analogues (44 ± 2% bound for **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and 40 ± 2% bound for **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A) and the reference tracer **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (36 ± 5% bound; *p* \> 0.05 for all comparisons).^[@ref17]^ Hence, the difference in lipophilicity did not seem to affect the serum binding ability of the different hybrid traceranalogues.

![Plasma protein interactions portraying (A) no significant difference (*p* \> 0.05) in the plasma protein binding of the heterobifunctional tracers compared to the alternative branched design and high stability over a 24 h timespan for both heterobifunctional tracers using (B) absorbance and (C) fluorescence measurements.](ao-2019-01484q_0001){#fig1}

Dye stabilities of \>94% were found after incubation with non-heat-inactivated serum (24 h; 37 °C), which was in line with earlier reports for Cy5 dyes^[@ref22],[@ref28]^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B,C).

In Vitro Localization and Receptor Affinity {#sec2.4}
-------------------------------------------

Fluorescence confocal imaging in mixed-cell culture experiments revealed comparable uptake of the reference tracer **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}Ai) in α~V~β~3~-positive cells (Cy5-related uptake in red) compared to both **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}Aii) and **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}Aiii). Uptake in α~V~β~3~-negative cells present in the mixed-cell culture was not seen ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A,B, with green fluorescent protein (GFP)-tagged membranous reference in bright green). Blocking studies confirmed selective binding of the tracers to α~V~β~3~ ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B); incubation with unlabeled **c\[RGDyK\]** resulted in a statistically significant decrease in uptake of the reference tracer **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (94 ± 6%) and both triazole-containing tracers **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (86 ± 8%) and **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (83 ± 24%; [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C; *p* \< 0.0001).

![In vitro evaluation of the hybrid tracers. Fluorescence confocal microscopy images of a mixed-cell culture of (A) α~V~β~3~-positive Geβ3 and α~V~β~3~-negative MDAMB231 X4 cells incubated with the reference tracer (i) **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, (ii) **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, (iii) **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**. (B) The same cell lines after blocking with c\[RGDyK\] prior to incubation with one of the hybrid tracers. For additional reference, cell nuclei were stained with Hoechst (in blue), and the intrinsic membranous GFP expression of the MDAMB231 X4 cells was used to discriminate between the two cell lines (bright green). (C) Quantified evaluation of the percentage of signal decrease between (A) and (B) (blocked; checkered) *p* \< 0.0001, *n* ≥ 13. (D) Combined saturation curves of the affinity of **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, and **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (with the binding affinity (*K*~D~) of the tracers in nanomolar), *n* = 3.](ao-2019-01484q_0002){#fig2}

Flow-cytometry-based affinity measurements showed that the affinity of **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** for the α~v~β~3~ integrin (*K*~D~ = 17.5 ± 6.0; [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D) was significantly increased compared to the previously reported affinity of the reference tracer **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (*K*~D~ = 30.3 ± 5.7, *p* \> 0.0001; [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D, black).^[@ref17],[@ref21]^ The receptor affinity of **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** was significantly lower (*K*~D~ = 76.5 ± 18.3, *p* \> 0.0001; [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D, green) than that of the reference tracer **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, but still in the lower nanomolar range.

In Vivo Imaging and Biodistribution {#sec2.5}
-----------------------------------

To assess the effect of implementation of triazole-based click chemistry on the in vivo targeting efficiency and pharmacokinetics of the RGD tracers, **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** were directly compared to the end-conjugated reference tracer **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**. To this end, single-photon emission computed tomography (SPECT) imaging ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A), fluorescence imaging ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B), and quantitative assessment of the in vivo biodistribution of **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C) were performed using identical experimental settings as used previously (i.e., at 24 h after intravenous administration of 1 nmol of the respective hybrid RGD tracer derivative).^[@ref17],[@ref21]^ Both SPECT and fluorescence imaging of tumor-bearing mice resulted in tumor visualization after administration of **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, or **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A,B, respectively, i and ii; tumor encircled in red). Besides tumor visualization, SPECT imaging also enabled visual assessment of the biodistribution of the hybrid tracers, revealing a dominant kidney accumulation for all compounds ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A) and a relatively high uptake in other nontargeted organs for **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}Aiii). It was suspected that the visibility of the tumor when using **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** was further impeded by the location of the tumor.

![In vivo imaging and biodistribution. In vivo (A) SPECT images and (B) accompanying fluorescence images of 4T1-tumor-bearing mice acquired at 24 h after administration of 1 nmol of the reference tracer **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (i), **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (ii), and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (iii). Tumor is encircled in red. (C) Quantified biodistribution (% ID/g) of **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (purple) and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (green; *n* = 6 per compound). For reference, biodistribution of **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (black) was included as previously presented by Bunschoten et al.^[@ref17]^ Significance between the hybrid triazole-containing RGD conjugates and the reference annotated as: \*\*\*\**p* ≤ 0.0001, \*\*\**p* ≤ 0.001, \*\**p* ≤ 0.01, \**p* ≤ 0.05, and ns = *p* \> 0.05.](ao-2019-01484q_0003){#fig3}

The ex vivo biodistribution data not only underlined the imaging observations but also revealed differences ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C), e.g., in tumor uptake: **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** have tumor uptakes of 3.5 ± 1.7 and 2.9 ± 1.7% ID/g, respectively. **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, with a tumor uptake of 1.6 ± 0.3% ID/g, is significantly different from **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (*p* = 0.0312), but is in the same range as **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (*p* \> 0.05). The tumor-to-muscle ratios (T/M) of both **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (4.8 ± 2.1) and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (5.1 ± 1.5) were, however, clearly negatively affected by nonspecific signal present in adjoining muscle tissue; compared to these two tracers, the T/M of the reference tracer **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** was found to be superior (12.8 ± 1.8; *p* \< 0.0001 for both comparisons). Nevertheless, the tumors could still be visualized in vivo with fluorescence imaging despite the lower T/M ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B).

Affinity values are generally used to explain T/M ratios.^[@ref17]^ In this case, however, the measured affinities did not directly link to the tumor uptake or T/M ratios; both **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** have an affinity in the same nanomolar range as **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, but their T/M ratio is significantly reduced compared to the reference tracer **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (*p* \< 0.0001). Other than affinity, differences in charge, lipophilicity, and/or serum binding also influence the T/M ratio. In this case, a trend (albeit nonsignificant) was observed for serum binding (**\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** \> **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** \> **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**; see [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A; *n* = 3), which seemed to translate to changes in the biodistribution values; in vivo, the trend became more pronounced and differences were statistically significant. The fact that this uptake pattern was similar for all of the evaluated organs ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C; *n* = 6) further suggested a generic effect; serum binding has e.g. been the culprit for such observations in previously reported results.^[@ref27]^

For all compounds, renal retention was by far the highest, and the uptake of **\[**^**111**^**In\]DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **\[**^**111**^**In\]DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** was significantly higher compared to that of the reference tracer **\[**^**111**^**In\]DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]** (14.7 ± 3.2, 22.0 ± 5.7, and 3.0 ± 1.4% ID/g, respectively; *p* ≤ 0.0001). As the α~V~β~3~ integrin is ubiquitous in the kidney, some renal accumulation of the RGD-containing conjugates can be expected;^[@ref29],[@ref30]^ however, considering conditions between groups were identical, this explanation appeared inadequate. This effect could also not be explained based on the lipophilicity of the compounds (see above). Hence, it seems that the increase in renal uptake of the triazole-containing RGD hybrid tracers is attributable to the introduction of triazole-containing moieties formed by click chemistry. Literature indicates that some triazoles, e.g., Isavuconazole, are characterized by prolonged high kidney uptake^[@ref31]^ and that 3-amino-1,2,3-triazole irreversibly binds to catalase proteins,^[@ref32],[@ref33]^ thus implying that these moieties may induce this behavior. It is generally known that molecular alterations and their size have an undisputed effect on the biodistribution, but no prior research regarding the influence of the moieties resulting from copper-free click chemistry has been published to date to the best of our knowledge.

Besides SPAAC and its triazole product, other forms of bioorthogonal click chemistry such as the isocyanide \[4 + 1\] cyclocaddition or inverse electron demand Diels--Alder (IEDDA) could also be employed in the design of a hybrid tracer. However, while IEDDA (*k*= 1--10 × 10^6^M^--1^s^--1^) is considerably faster than SPAAC  (*k* = 10^--2^--1 M^--1^ s^--1^)^[@ref34]^ and has been used previously in pretargeting strategies,^[@ref35],[@ref36]^ the effect of IEDDA on the in vivo characteristics of a tracer without an antibody has not yet been investigated. That being said, given the relatively large effects that the triazole-containing moieties have been shown to exert, it would be of great interest to compare the effect of both types of copper-free click chemistry in an in vivo setting.

As previously mentioned, the 1,2,3-triazole-containing moiety introduced by click chemistry seemed to have a negative effect on the pharmacokinetics of RGD-based hybrid tracers, but the utility of the heterobifunctional design regarding other targets and/or other targeting moieties should be considered in future studies considering e.g. receptor pockets can vary. The composition of the hybrid tracer plays a large role in the pharmacokinetics of small-molecule-based hybrid tracers,^[@ref20]^ but such an effect could prove negligible with larger structures such as nanobody-, antibody-, or nanoparticle-based hybrid tracers. Further exploration of whether this design holds promise for other targets, with or without click chemistry, is thus warranted.

Conclusions {#sec3}
===========

Despite the tracer's stability and good in vitro performance of triazole-based hybrid tracers, biodistribution data indicated that incorporation of the relatively bulky chemical modifications used for the copper-free click conjugation in RGD-targeting hybrid tracer design has a negative effect on its pharmacokinetics, although the tumors could still be visualized. Thus, the design could hold promise for other targets and/or targeting moieties.

Methods {#sec4}
=======

All chemicals were obtained from commercial sources and used without further purification. Solvents were obtained from Actu-All Chemicals (Oss, The Netherlands) in high-performance liquid chromatography (HPLC) or peptide grade and used without further purification. The reactions were monitored by thin-layer chromatography (TLC) and/or mass spectrometry using a Bruker microflex LRF matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF). HPLC was performed on a Waters (Etten-Leur, The Netherlands) HPLC system using a 1525EF pump and a 2489 UV/vis detector. For preparative HPLC, a Dr. Maisch GmbH (Ammerbuch, Germany) Reprosil-Pur 120 C18-AQ 10 μm (250 × 20 mm^2^) column was used (12 mL/min). For semipreparative HPLC, a Dr. Maisch GmbH Reprosil-Pur C18-AQ 10 μm (250 × 10 mm^2^) or a Waters XBridge BEH C8 10 μm (250 × 10 mm^2^) Prep OBD column was used (5 mL/min). For analytical HPLC, a Dr. Maisch GmbH Reprosil-Pur C18-AQ 5 μm (250 × 4.6 mm^2^) column was used. For all HPLC runs, a gradient of 0.1% trifluoroacetic acid (TFA) in H~2~O/CH~3~CN 95:5 to 0.1% TFA in H~2~O/CH~3~CN 5:95 in 40 min was used. Nuclear magnetic resonance (NMR) spectra were taken using a Bruker DPX-300 spectrometer (300 MHz ^1^H NMR, 75 MHz ^13^C NMR), and chemical shifts (δ) are reported relative to TMS (δ = 0) and/or referenced to the solvent in which they were measured. Abbreviations used include singlet (s), doublet (d), doublet of doublets (dd), triplet (t), and unresolved multiplet (m). Full ^1^H NMR spectra are provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01484/suppl_file/ao9b01484_si_001.pdf) available online.

Synthesis {#sec4.1}
---------

### (SO~3~)Indole, Indole, and Indole-COOH {#sec4.1.1}

**(SO~3~)Indole, Indole** and **Indole-COOH** were synthesized according to earlier published procedures.^[@ref37]^ All products were directly used without further purification.

### (SO~3~)Indole-AmineC4Phth {#sec4.1.2}

**(SO**~**3**~**)Indole-AmineC4Phth** was synthesized inspired by adjusted synthesis methods.^[@ref37],[@ref38]^ Briefly, **(SO**~**3**~**)Indole** (25 mmol) and 1-(4-bromobutyl)pyrrolidine-2,5-dione (75.0 mmol) were dissolved in sulfolane (40 mL) and left stirring at 90 °C for 24 h under nitrogen atmosphere. The resulting mixture was, after cooling down to room temperature (r.t.), precipitated by adding to CH~3~OH. The product was washed twice with ethyl acetate and diethyl ether and dried in vacuo, resulting in a brownish powder (5.9 g), which was used without any further purification.

### DTPA-NHS {#sec4.1.3}

DTPA(*t*Bu)~4~ (100.0 mg, 161.9 μmol), dipyrrolidino(*N*-succinimidyloxy)carbenium hexafluorophosphate (HSPyU) (73.0 mg, 178.1 μmol), and *N*,*N*-diisopropylethylamine (DiPEA) (141.0 μL, 809.3 μmol) were dissolved in CH~2~Cl~2~ (5 mL, dried on 4 Å molecular sieves) and stirred for 15 h at r.t. The crude product was used without further purification in the following reaction steps. *m*/*z* \[M + H\]^+^ calcd. 715.9, found 715.5.

### DTPA-Ethylene Diamine {#sec4.1.4}

DTPA-NHS (57.5 mg, 93.1 μmol), *N*-Boc-ethylenediamine (12.8 μL, 81.0 μmol), and DiPEA (28.2 μL, 160.9 μmol) in CH~2~Cl~2~ (2.5 mL) were stirred for 30 min until full conversion according to TLC and MALDI-TOF. The solvent was removed in vacuo and 95:5 TFA/H~2~O (2 mL) was added followed by stirring for 2 h. The product was precipitated in diethyl ether (45 mL), centrifuged, and decanted. This was repeated twice, and the precipitate was desiccated and used without further purification. *m*/*z* \[M + H\]^+^ calcd. 436.4, found 436.0.

### DTPA--DBCO {#sec4.1.5}

**DTPA-ethylene diamine** (23.0 μmol) and triethylamine (23.0 μmol) were dissolved in dimethylformamide (DMF) (120.0 μL) and stirred at 30 °C. DBCO-NHS (15.3 μmol) was dissolved in DMF (580 μL) and added to the DTPA-ethylene diamine solution before stirring at 30 °C for 7 h. Subsequently, DiPEA (115.0 μmol) was added and the mixture was stirred at 30 °C overnight before cooling down to r.t. and precipitating in ice-cold diethyl ether. The precipitate was collected, and residual solvents were removed in vacuo. The crude, white solid was purified by prep-HPLC to obtain a white solid (0.8 mg), which was used without any further purification.

### DTPA--BCN {#sec4.1.6}

**DTPA-ethylene diamine** (121 μmol) was dissolved in DMSO (800 μL). BCN-NHS (81 μmol, purchased at Sigma-Aldrich Cat. No. 744867) and DIPEA (810 μmol) were dissolved in DMSO (200 μL) and added to the DTPA-ethylene diamine solution before stirring overnight at r.t. After rinsing the reaction vial with H~2~O and CH~3~CN, the solvents and DIPEA were removed by centrifugal evaporation at 50 °C and \<0.128 mbar for 5 h. The remaining, slightly yellow oil was used without further purification.

### c\[RGDyK\] {#sec4.1.7}

This compound was synthesized as previously described.^[@ref17]^

### Phth-(SO~3~)Cy5-COOH {#sec4.1.8}

The synthesis of the Cy5 dye was performed based on literature procedures.^[@ref39]^ In short, **Indole-COOH** (1.1 g, 4.0 mmol) and *N*-((2*E*,4*E*)-4-(phenylimino)but-2-en-1-yl)aniline (1.2 g, 4.4 mmol) were dissolved in acetic acid/acetic anhydride (1:1, 30 mL) and left stirring at 60 °C; progress of the reaction was monitored by absorption spectroscopy. After stirring at 60 °C overnight, the mixture was heated to 120 °C. The crude product was dissolved in DMF/CH~2~Cl~2~ (70 mL; 1:1) after precipitation in diethyl ether (600 mL). Merrifield resin (1.2 g, 2.0 mmol) was suspended in CH~2~Cl~2~ for 5 min and was then left to bubble in 20% TFA in CH~2~Cl~2~ (50.0 mL) for 1 h and in 20% DiPEA (50.0 mL) in CH~2~Cl~2~ for 15 min. The dissolved hemicyanine was then added to the preconditioned resin. After bubbling through N~2~ for 1 h, the resin was washed with DMF/CH~2~Cl~2~ (20 mL; 1:1) thrice. **(SO**~**3**~**)Indole-AmineC4Phth** (0.44 g, 1.0 mmol) was dissolved in pyridine/acetic anhydride (40 mL; 3:1) and added to the resin. The resulting reaction mixture was shaken overnight at r.t. Afterward, the liquids were collected and the resin was washed with DMF and/or CH~2~Cl~2~ until the washings were light blue. The crude reaction mixture was concentrated in vacuo and separated by column chromatography (CH~2~Cl~2~: CH~3~OH) and then further purified by prep-HPLC, yielding a blue solid after lyophilization (39.0 mg, 5%) with a purity of 99%. *m*/*z* \[M + H\]^+^ calcd. 750.9, found 751.1. ^1^H NMR (300 MHz, MeOD) δ 8.23 (dt, *J* = 13.0 Hz, 2H), 7.79--7.88 (m, 4H), 7.23--7.54 (m, 8H), 6.63 (t, *J* = 12.4 Hz, 1H), 6.31 (d, *J* = 13.6 Hz, 2H), 4.15--4.18 (m, 4H), 3.78 (m, 2H), 2.35 (t, *J* = 2.35 Hz, 2H), 1.82--1.90 (m, 6H), 1.72--1.75 (m, 14H), 1.53 (m, 2H) ([Figure SI1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01484/suppl_file/ao9b01484_si_001.pdf)).

### H~2~N(SO~3~)-Cy5-COOH {#sec4.1.9}

Phth-(SO~3~)Cy5 -COOH (55.0 mg, 73.2 μmol) was dissolved in CH~3~NH~2~ (33 wt % in ethanol; 25 mL). After stirring for 21 h, the reaction appeared to be complete. Residual CH~3~NH~2~ and ethanol were removed in vacuo before dividing into two portions. The crude product was dissolved in H~2~O (0.1% v/v TFA) (3 mL) and CH~3~CN (0.1% v/v TFA) (1 mL), purified by means of reversed-phase (RP) preparative (prep)-HPLC, and after removal of solvents in vacuo, H~2~N(SO~3~)-Cy5-COOH was obtained as a blue solid (19.0 mg, 42%). *m*/*z* \[M + H\]^+^ calcd. 620.8, found 620.6. ^1^H NMR (300 MHz, DMSO) δ 12.01 (s, 1H), 8.37 (td, J = 13.0, 5.7 Hz, 2H), 7.83 (d, J = 1.4 Hz, 1H), 7.68--7.64 (m, 1H), 7.64--7.60 (m, 3H), 7.43 (s, 2H), 7.35--7.23 (m, 3H), 6.58 (d, J = 12.1 Hz, 1H), 6.31 (t, J = 13.9 Hz, 2H), 4.13 (d, J = 6.6 Hz, 5H), 2.80 (s, 2H), 2.20 (t, J = 7.1 Hz, 2H), 1.71 (s, 6H), 1.68 (s, 6H), 1.58--1.51 (m, 4H), 1.41--1.34 (m, 2H), 1.23 (s, 1H) ([Figure SI2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01484/suppl_file/ao9b01484_si_001.pdf)).

### N~3~(SO~3~)-Cy5-COOH {#sec4.1.10}

H~2~N(SO~3~)-Cy5-COOH (43.1 mg, 66.7 μmol) was dissolved in CH~3~OH (10 mL) before basifying with K~2~CO~3~ (180.0 μmol). CuSO~4~ (cat., in H~2~O) and 1*H*-imidazole-1-sulfonyl azide hydrochloride (80.0 μmol) were added, and the resulting mixture was stirred at r.t. under a N~2~ atmosphere for 3 h. Then, the solvent was removed in vacuo and the crude product was redissolved in H~2~O (0.1% v/v TFA) (3 mL) and CH~3~CN (0.1% v/v TFA) (1 mL) and purified by means of RP prep-HPLC. Solvents were removed in vacuo, yielding a blue solid (28.9 mg, 43%). *m*/*z* \[M + H\]^+^ calcd. 646.8, found 646.3. ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 8.35 (td, *J* = 13.2, 4.9 Hz, 2H), 7.81 (d, *J* = 1.5 Hz, 1H), 7.69--7.56 (m, 2H), 7.41 (d, *J* = 4.1 Hz, 2H), 7.34 (d, *J* = 8.3 Hz, 1H), 7.25 (dt, *J* = 12.4, 4.2 Hz, 1H), 6.58 (t, *J* = 12.3 Hz, 1H), 6.32 (dd, *J* = 13.8, 9.2 Hz, 2H), 4.48 (s, 5H), 4.11 (br s, *J* = 22.5 Hz, 4H), 2.20 (t, *J* = 7.1 Hz, 2H), 1.69 (d, *J* = 3.2 Hz, 14H), 1.60--1.47 (m, 2H), 1.46--1.28 (m, 2H), 1.11 (s, 2H) ([Figure SI3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01484/suppl_file/ao9b01484_si_001.pdf)).

### Phth(SO~3~)-Cy5-c\[RGDyK\] {#sec4.1.11}

**Phth-(SO**~**3**~**)Cy5-COOH** (20.0 mg, 26.7 μmol), HSPyU (12.0 mg, 29.3 μmol) and DiPEA (23.0 μL, 133.3 μmol) were dissolved in DMSO (400 μL, dried on 4 Å molecular sieves). After stirring for 30 min at r.t., 100% conversion was confirmed by TLC and MALDI-TOF. c\[RGDyK\] (18.0 mg, 29.3 μmol) and DiPEA (9.3 μL, 53.0 μmol) were added and the solution was stirred at r.t. for 72 h, whereafter TLC and MALDI-TOF indicated full consumption of c\[RGDyK\]. H~2~O (0.1% v/v TFA) (2.4 mL) and CH~3~CN (0.1% v/v TFA) (3 mL) were added, and the compound was purified by RP-HPLC and lyophilized, yielding a blue solid (10.0 mg, 28%). *m*/*z* \[M + H\]^+^ calcd. 1,352.6, found 1,351.8.

### H~2~N(SO~3~)-Cy5-c\[RGDyK\] {#sec4.1.12}

**Phth(SO**~**3**~**)-Cy5-c\[RGDyK\]** (10.0 mg, 7.4 μmol) was dissolved in DMF (6 mL), and CH~3~NH~2~ (33%wt in ethanol) (20 mL) was added. After stirring at r.t. for 16 h, the reaction was complete according to TLC and MALDI-TOF. Ethanol and CH~3~NH~2~ were removed in vacuo and the product was precipitated in diethyl ether (45 mL) and centrifuged. After decanting, the precipitate was washed with ethyl acetate (45 mL), centrifuged again, and this was repeated twice with diethyl ether (45 mL). The blue solid was desiccated, redissolved in H~2~O/CH~3~CN (4 mL; 1:1; 0.1% v/v TFA), and used without further purification. *m*/*z* \[M + H\]^+^ calcd. 1,222.5, found 1,222.2.

### N~3~(SO~3~)-Cy5-c\[RGDyK\] {#sec4.1.13}

**H**~**2**~**N(SO**~**3**~**)-Cy5-c\[RGDyK\]** (2.0 mg, 1.6 μmol) dissolved in 3:1 H~2~O/CH~3~CN (2 mL) and imidazole-1-sulfonyl azide hydrochloride (0.7 mg, 3.3 μmol) dissolved in H~2~O/CH~3~CN (3:1; 500 μL), *N*-methylmorpholine (0.5 μL, 4.3 μmol), and CuSO~4~ in H~2~O (cat.) were stirred at r.t. for 5.5 h. Ethyl acetate (40 mL) and CH~3~OH (10 mL) were added, leading to precipitation of the crude product. The suspension was centrifuged, decanted, washed twice with diethyl ether, and desiccated. Purification by RP-HPLC followed by lyophilization yielded a blue solid (490.0 μg, 24%). *m*/*z* \[M + H\]^+^ calcd. 1,248.5, found 1,248.1.

### DTPA.DBCO.N~3~(SO~3~)-Cy5-c\[RGDyK\] {#sec4.1.14}

**N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (150.0 μg, 120.2 nmol) and **DTPA--DBCO** (294.0 μg, 480.8 nmol) were stirred in DMSO/PBS/H~2~O (2:1:6; 450 μL) for 11.5 h. Then, H~2~O (0.1% v/v TFA) (600 μL) was added and the compound was purified by RP-HPLC yielding a blue solid after lyophilization (185.0 μg, 78%). *m*/*z* \[M + H\]^+^ calcd. 1,971.2, found 1,970.1.

### DTPA.BCN.N~3~(SO~3~)-Cy5-c\[RGDyK\] {#sec4.1.15}

**N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (150.0 μg, 120.2 nmol) and **DTPA--BCN** (374.0 μg, 480.8 nmol) were stirred in DMSO/PBS/H~2~O (2:1:7; 500 μL) for 11.5 h. Then, H~2~O (0.1% v/v TFA; 600 μL) was added and the compound was purified by RP-HPLC (C8) yielding a blue solid after lyophilization (30.7 μg, 14%). *m*/*z* \[M + H\]^+^ calcd. 1,860.1, found 1,859.4.

Photophysical Properties {#sec4.2}
------------------------

Absorption coefficient (ε), quantum yield (Φ~F~), and maximum absorption/emission measurements of **N**~**3**~**(SO**~**3**~**)-Cy5-COOH** and its two conjugates (**DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** and **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**), serum stability analysis, and serum binding experiments were performed according to the previously described methods.^[@ref21],[@ref22]^ The brightness of the hybrid tracers was based on their respective quantum yield and ε~fluorophore~.

Lipophilicity {#sec4.3}
-------------

log *P*~(o/w)~ was calculated according to previously published methods.^[@ref43]^ In short, to a solution of 0.5--1 MBq of ^99m^Tc radiolabeled hybrid tracer in 500 μL of phosphate-buffered saline (PBS, pH 7.4), 500 μL of 1-octanol was added (*n* = 6). Vials were vigorously shaken on a IKA VXR basic Vibrax orbital shaker (IKA-Werke GmbH & Co. KG, Staufen, Germany) for 3 min and subsequently centrifuged at 6000 rpm for 5 min in a Fisher Scientific MicroV centrifuge (Fisher Scientific, Hampton) to achieve quantitative phase separation. The activity concentrations in 100 μL samples of both the aqueous and organic phases were measured in a PerkinElmer Wizard2 γ-counter (PerkinElmer, Waltham).

In Vitro Tracer Specificity {#sec4.4}
---------------------------

A mix of α~V~β~3~-integrin-expressing Geβ3 cells and MDAMB231 X4 cells^[@ref40]^ was seeded onto coverslips (ø35 mm; MatTek Corporation) and incubated at 37 °C in 2 mL of medium for 48 h. One hour prior to imaging, the cells were incubated (37 °C) with **DTPA-Lys(Cy5(SO**~**3**~**)methyl)-Cys-c\[RGDyK\]**, **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**, or **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** (1 μM). For blocking experiments, 1 μM unlabeled c\[RGDyK\] was added 1 h prior to addition of **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** or **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]**. Prior to imaging, the cells were washed three times with PBS. Confocal microscopy was performed on viable cells, using an SP8 WLL fluorescence confocal microscope (Leica Microsystems, Wetzlar). For additional reference, the nuclei of the cells were stained with Hoechst 33342 (1 mg/mL stock, Thermo Fisher). Sequential scanning settings were used to visualize the different fluorescent features: Hoechst (nuclear staining; λ~ex~ 405 nm, λ~em~ 42--470 nm), intrinsic GFP (λ~ex~ 500 nm, λ~em~ 500--550 nm; MDAMB231 X4 only), and Cy5 (λ~ex~ 633 nm, λ~em~ 650--700 nm). Quantification of cellular uptake was performed as previously described.^[@ref15]^ In images depicting the Cy5-related signal intensity, regions of interest were placed around the whole cell (minimum of 13 cells per image) using Fuji software, whereafter the pixel intensity per cell could be determined. Unblocked and blocked conditions were evaluated for all three tracers (*n* = 3 experiments per condition). For the unblocked conditions, the percentage of fluorescence uptake (intensity per cell) was set at 100%. The percentage fluorescence uptake after blocking was determined relative to the unblocked condition.

Receptor Affinity {#sec4.5}
-----------------

The affinity (*K*~D~) of the tracers for Geβ3 cells was determined by saturation binding experiments. To this end, 3 × 10^5^ cells were incubated for 1 h at 4 °C with different concentrations of either **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** or **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** ranging from 0 to 1500 nM. To accomplish this, Geβ3 cells were trypsinized, pelleted (4 min, 1200 rpm, 4 °C), and resuspended in Dulbecco's modified Eagle's medium (DMEM; enriched with 5% fetal bovine serum and 1% penicillin/strepcillin (1:1 v/v)) to obtain a concentration of 6 × 10^6^ cells/mL. Subsequently, 50 μL of the cell suspension (3 × 10^5^ cells) was added to 50 μL of the tracer in cold DMEM (0--3000 nM). After 1 h incubation at 4 °C, the samples were washed three times with 0.1% fetal calf serum in cold PBS by pelleting (4 min, 1200 rpm, 4 °C) and subsequently resuspended in 150 μL of 0.1% fetal calf serum in cold PBS. The samples were then measured by flow cytometry using an LSR-II after excitation at 633 nm and collecting the signal in the APC-A channel. All experiments were performed in triplicate.

Normalized geometric means were fitted with equations in the GraphPad Prism 7 software. The *K*~D~ values were calculated using the "Binding--Saturation, One site--Total" nonlinear regression equation ([eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}), with the background value set at 0.where *y* = normalized fluorescence, *B*~max~ = maximum specific binding in the units of the *y*-axis, *x* = concentration of the hybrid labeled tracer, *K*~D~ = equilibrium dissociation constant of the hybrid labeled tracer in nanomolar.

Radiolabeling {#sec4.6}
-------------

For logP experiments, 66 μL of 10 μM Tin(II)chloride dihydrate in sodium acetate buffer (250 mM, pH 4.0) and 6 MBq of ^99m^Tc in 7--11 μL saline were added to 1 nmol compound dissolved in a NH~4~OAc buffer (250 mM, pH 5.5). After shaking at room temperature for 5 min, the radiochemical purity was determined to be \>90% using iTLC with PBS as eluent.

For biodistribution experiments, 4 nmol of either **DTPA.DBCO.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** or **DTPA.BCN.N**~**3**~**(SO**~**3**~**)-Cy5-c\[RGDyK\]** was dissolved in a NH~4~OAc buffer (0.25 M; pH = 5.5) and mixed with 12.2 μL of an ^111^InCl~3~ solution in 0.05 M HCl (0.33 MBq/μL, Mallinckrodt Medical, Petten, The Netherlands). The mixtures were shaken for 1 h at r.t. After addition of HCl (0.05 M; 232 μL), the mixtures were supplemented with isotonic PBS to obtain a volume of 600 μL, and 150 μL (1 nmol) per mouse was then injected.

For combined imaging and biodistribution experiments, 2 nmol of each compound, dissolved in a NH~4~OAc buffer (0.25 M; pH = 5.5), was mixed with 121.9 μL of an ^111^InCl~3~ solution in 0.05 M HCl (0.33 MBq/μL, Mallinckrodt Medical, Petten, The Netherlands). The mixtures were shaken for 1 h at r.t., whereafter the mixtures were supplemented with isotonic PBS to obtain an injection volume of 300 μL.

In Vivo Imaging and Biodistribution {#sec4.7}
-----------------------------------

The 4T1 tumor model was generated in BALB/c nude mice, as previously described.^[@ref27]^ The animal studies were approved by the institutional Animal Ethics Committee of the Leiden University Medical Center.

Imaging and biodistribution were performed 24 h after intravenous tracer (1 nmol) administration (*n* = 6 animals for each tracer; *n* = 4 biodistribution only, 2 SPECT imaging/biodistribution). SPECT imaging was performed as previously described.^[@ref17],[@ref21]^ Maximum intensity projection images were generated and analyzed using Matlab software (MathWorks, Natick, MA) according to previously described methods.^[@ref21]^ Hereafter, fluorescence imaging was performed in vivo and ex vivo using an IVIS Spectrum imaging system (Caliper Life Science, Hopkinton, MA). Images were acquired at λ~ex~ = 640 nm, λ~em~ = 680 nm, and image analysis was performed using the Living Image software from Xenogen v 3.2 (Caliper LS). In vivo fluorescence images were used to provide a direct link to the in vivo SPECT images.

For assessment of the biodistribution of the tracers, the mice were sacrificed and organs and tissues were surgically excised. The amount of radioactivity in the tissues was counted using a γ counter (2470 automatic γ counter, PerkinElmer, 245 keV, 60 s), and the percentage of the injected dose per gram of tissue (% ID/g) was calculated according to previously described methods.^[@ref17]^

Statistical Analysis {#sec4.8}
--------------------

Analytical data were expressed as mean and standard deviation as calculated using Microsoft Excel and GraphPad Prism 7 software. In this study, significance of two mean values was calculated by the unpaired *t*-test or one-way ANOVA unless noted otherwise. The level of significance was set at *p* \< 0.05.
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